Liver Diseases Therapeutics Market Size, Product Cost Analysis and Forecast 2030

Liver Diseases Therapeutics Market Summary

The global liver disease therapeutics market size was estimated at USD 20.31 billion in 2024 and is projected to reach USD 40.29 billion by 2033, expanding at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2033. The market’s expansion is primarily driven by the increasing prevalence of non-alcoholic fatty liver disease (NAFLD), hepatitis B and C, and alcohol-related liver disorders. Additionally, advancements in drug development, increasing awareness of liver health, and the global rise in obesity and diabetes—which are known risk factors for liver disease—are contributing significantly to the growing demand for effective liver disease therapeutics.

The escalating burden of liver diseases globally serves as a key catalyst for the market. Both chronic and acute liver conditions—including viral hepatitis (HBV and HCV), NAFLD, alcohol-associated liver disease (ALD), and hepatocellular carcinoma (HCC)—are becoming more prevalent. This has created a robust demand for therapeutic options at all stages of liver disease progression. From early antiviral interventions to targeted therapies for liver cancer, the increasing clinical need is pushing pharmaceutical innovations and market growth.

Key Market Trends & Insights

• In 2024, the antiviral drugs segment accounted for the largest revenue share of 39.84% in the global market. This dominance is largely due to the significant prevalence of chronic viral hepatitis worldwide. The prolonged treatment regimens for hepatitis B, combined with the high cost of direct-acting antivirals (DAAs) used in hepatitis C therapy, underscore the central role antiviral medications play in liver disease management and revenue generation in the sector.
• The hepatitis segment held the largest revenue share of 40.44% in 2024. This is attributed to the immense global burden of chronic hepatitis, which continues to affect more than 300 million individuals. Approximately 254 million people live with chronic HBV and around 50 million with chronic HCV, making it a prominent public health concern. The consistent success of antiviral treatment options in managing hepatitis further fuels the dominance of this segment.
• In 2024, North America led the global liver disease therapeutics market, accounting for 39.87% of the total revenue. The region's leadership is supported by a rising incidence of liver diseases, a well-developed healthcare system, high healthcare spending, and the presence of cutting-edge therapies. The United States held the majority of the North American share, due to its sizable patient base, advanced treatment infrastructure, and strong adoption rate of new therapeutic modalities.
• Europe also captured a significant market share in 2024, largely driven by the growing prevalence of hepatitis, liver cancer, and NAFLD. The region continues to experience health challenges linked to alcohol consumption and aging populations. However, greater public health awareness and national screening initiatives have resulted in improved early diagnosis rates, supporting timely and effective treatment across the continent.
• Asia Pacific is expected to witness the fastest growth in the liver disease therapeutics market, with a projected CAGR of 9.19% over the forecast period. The region bears a high disease burden, particularly from hepatitis B and C, as well as increasing NAFLD rates. Improving healthcare systems and rising public health investment in countries like China, India, and Japan are expected to accelerate access to diagnostics and treatments, boosting regional market expansion.
• The liver disease therapeutics market in Latin America is experiencing steady development. Increasing prevalence of hepatitis B and C, NAFLD, and alcohol-related liver issues—compounded by rising rates of obesity and excessive alcohol use—are driving the demand for liver treatments in countries such as Brazil, Mexico, and Argentina. Improving healthcare access and rising awareness about liver health further contribute to regional market growth.
• The Middle East & Africa region is also showing consistent market progression. This is due to the growing incidence of hepatitis, liver cancer, and NAFLD associated with metabolic disorders like diabetes and obesity. Public health campaigns, better diagnostic practices, and expanding vaccination efforts are enhancing early detection and improving patient outcomes across the region.

Order a free sample PDF of the Liver Diseases Therapeutics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 20.31 Billion
• 2033 Projected Market Size: USD 40.29 Billion
• CAGR (2025-2033): 7.9%
• North America: Largest market in 2024
• Asia Pacific: Fastest-growing market

Key Players

• Gilead Sciences, Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• GSK plc

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global liver disease therapeutics market is expected to grow significantly, driven by rising disease prevalence, increasing healthcare awareness, and advancements in therapeutic technologies. Key contributors include chronic hepatitis, NAFLD, and liver cancer, with antiviral treatments and targeted therapies gaining momentum. Regional growth is supported by healthcare infrastructure development and public health initiatives, particularly in Asia Pacific and North America. As lifestyle-related conditions continue to impact liver health, the demand for innovative and accessible treatment options is likely to intensify. Industry efforts in early diagnosis, drug innovation, and patient education will be pivotal in sustaining long-term market expansion globally.